 Brian Day
Concepts (546)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antioxidants | 43 | 2024 | 529 | 6.260 |
Why?
| | Glutathione | 28 | 2017 | 293 | 5.400 |
Why?
| | Metalloporphyrins | 26 | 2024 | 103 | 3.950 |
Why?
| | Oxidative Stress | 42 | 2024 | 1068 | 3.820 |
Why?
| | Thiocyanates | 6 | 2019 | 29 | 2.000 |
Why?
| | Bronchoalveolar Lavage Fluid | 15 | 2021 | 580 | 1.930 |
Why?
| | Lung | 23 | 2023 | 3521 | 1.830 |
Why?
| | Reactive Oxygen Species | 21 | 2018 | 522 | 1.770 |
Why?
| | Mustard Gas | 7 | 2016 | 117 | 1.700 |
Why?
| | Chemical Warfare Agents | 4 | 2016 | 119 | 1.630 |
Why?
| | Particulate Matter | 4 | 2021 | 185 | 1.600 |
Why?
| | ATP-Binding Cassette Transporters | 5 | 2012 | 122 | 1.350 |
Why?
| | Smoking | 9 | 2015 | 1382 | 1.200 |
Why?
| | Immunity, Innate | 3 | 2019 | 720 | 1.040 |
Why?
| | Lung Injury | 4 | 2023 | 192 | 0.970 |
Why?
| | Antidotes | 3 | 2016 | 135 | 0.950 |
Why?
| | Lung Diseases | 4 | 2021 | 690 | 0.940 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2012 | 287 | 0.920 |
Why?
| | Mesalamine | 2 | 2017 | 8 | 0.920 |
Why?
| | Animals | 67 | 2024 | 31570 | 0.900 |
Why?
| | Flavonoids | 3 | 2011 | 66 | 0.900 |
Why?
| | Inflammation | 11 | 2020 | 2465 | 0.890 |
Why?
| | Berylliosis | 4 | 2017 | 177 | 0.880 |
Why?
| | Cystic Fibrosis | 4 | 2020 | 955 | 0.860 |
Why?
| | Mitochondria | 11 | 2015 | 744 | 0.850 |
Why?
| | Pneumonia | 2 | 2020 | 563 | 0.840 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2023 | 1128 | 0.840 |
Why?
| | Superoxide Dismutase | 12 | 2015 | 305 | 0.840 |
Why?
| | Molecular Mimicry | 3 | 2008 | 35 | 0.730 |
Why?
| | Acetylcysteine | 5 | 2016 | 141 | 0.710 |
Why?
| | Inhalation Exposure | 5 | 2016 | 96 | 0.700 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2020 | 22 | 0.700 |
Why?
| | Interleukin-33 | 1 | 2020 | 38 | 0.690 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 219 | 0.690 |
Why?
| | Epithelial Cells | 9 | 2022 | 946 | 0.680 |
Why?
| | Oxidation-Reduction | 14 | 2017 | 917 | 0.680 |
Why?
| | Thioredoxin-Disulfide Reductase | 3 | 2015 | 14 | 0.670 |
Why?
| | Neuroprotective Agents | 5 | 2021 | 102 | 0.650 |
Why?
| | Mice | 35 | 2021 | 14847 | 0.650 |
Why?
| | Prodrugs | 1 | 2019 | 42 | 0.650 |
Why?
| | Neoplasm Proteins | 4 | 2014 | 385 | 0.640 |
Why?
| | Chalcones | 5 | 2012 | 9 | 0.640 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1472 | 0.600 |
Why?
| | Inflammation Mediators | 5 | 2018 | 475 | 0.600 |
Why?
| | Allergens | 1 | 2021 | 410 | 0.590 |
Why?
| | Beryllium | 3 | 2009 | 146 | 0.580 |
Why?
| | Electronic Nicotine Delivery Systems | 3 | 2023 | 71 | 0.570 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 192 | 0.560 |
Why?
| | Cell Line | 13 | 2020 | 2629 | 0.550 |
Why?
| | Deoxyguanosine | 3 | 2016 | 26 | 0.550 |
Why?
| | Wound Healing | 1 | 2019 | 254 | 0.550 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 4682 | 0.540 |
Why?
| | Organometallic Compounds | 2 | 2009 | 98 | 0.540 |
Why?
| | Manganese | 4 | 2024 | 55 | 0.530 |
Why?
| | Free Radical Scavengers | 6 | 2013 | 78 | 0.530 |
Why?
| | Catalase | 4 | 2013 | 118 | 0.520 |
Why?
| | Industrial Waste | 1 | 2015 | 5 | 0.510 |
Why?
| | War Exposure | 1 | 2015 | 10 | 0.510 |
Why?
| | Immunity, Cellular | 1 | 2017 | 247 | 0.510 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2004 | 82 | 0.490 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2016 | 58 | 0.490 |
Why?
| | Peroxidases | 1 | 2015 | 25 | 0.480 |
Why?
| | Respiratory Mucosa | 4 | 2011 | 252 | 0.480 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 296 | 0.480 |
Why?
| | Lymphocytes | 3 | 2017 | 327 | 0.470 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2013 | 71 | 0.460 |
Why?
| | Skin | 3 | 2014 | 653 | 0.460 |
Why?
| | Respiratory System | 1 | 2015 | 137 | 0.450 |
Why?
| | Rats, Sprague-Dawley | 14 | 2024 | 2182 | 0.440 |
Why?
| | Afghanistan | 4 | 2021 | 108 | 0.430 |
Why?
| | Cell Survival | 8 | 2014 | 1014 | 0.420 |
Why?
| | Cytokines | 7 | 2018 | 1824 | 0.420 |
Why?
| | Cell Proliferation | 6 | 2017 | 2173 | 0.420 |
Why?
| | Macrophages, Alveolar | 3 | 2011 | 348 | 0.410 |
Why?
| | Rats | 17 | 2024 | 4913 | 0.410 |
Why?
| | DNA, Mitochondrial | 4 | 2009 | 182 | 0.400 |
Why?
| | Macrophages | 6 | 2020 | 1259 | 0.390 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2012 | 12 | 0.390 |
Why?
| | Environmental Exposure | 1 | 2015 | 372 | 0.390 |
Why?
| | Influenza A virus | 2 | 2023 | 90 | 0.390 |
Why?
| | DNA | 4 | 2016 | 1350 | 0.390 |
Why?
| | Chemokines, CC | 1 | 2012 | 28 | 0.390 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 445 | 0.390 |
Why?
| | Humans | 53 | 2023 | 114080 | 0.390 |
Why?
| | Pinocytosis | 1 | 2011 | 10 | 0.390 |
Why?
| | Glutathione Peroxidase | 2 | 2008 | 40 | 0.380 |
Why?
| | Nerve Agents | 2 | 2024 | 4 | 0.380 |
Why?
| | Smoke | 3 | 2013 | 123 | 0.380 |
Why?
| | Extracellular Space | 2 | 2011 | 116 | 0.380 |
Why?
| | Chalcone | 1 | 2011 | 2 | 0.380 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2011 | 110 | 0.380 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2011 | 145 | 0.370 |
Why?
| | Doxorubicin | 2 | 2011 | 286 | 0.360 |
Why?
| | Adaptation, Physiological | 2 | 2011 | 484 | 0.360 |
Why?
| | Membrane Transport Proteins | 1 | 2012 | 138 | 0.360 |
Why?
| | Macrophage Activation | 1 | 2011 | 163 | 0.350 |
Why?
| | Virus Diseases | 2 | 2023 | 195 | 0.350 |
Why?
| | Lung Neoplasms | 4 | 2011 | 2159 | 0.340 |
Why?
| | Sulfasalazine | 1 | 2009 | 21 | 0.340 |
Why?
| | Chelating Agents | 1 | 2009 | 61 | 0.330 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 2699 | 0.330 |
Why?
| | Male | 36 | 2021 | 55420 | 0.330 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 21 | 0.330 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 76 | 0.320 |
Why?
| | Adenosine Triphosphate | 2 | 2015 | 428 | 0.320 |
Why?
| | Oxidants | 4 | 2019 | 112 | 0.310 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 184 | 0.310 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 32 | 0.310 |
Why?
| | Status Epilepticus | 3 | 2017 | 32 | 0.310 |
Why?
| | Mycoplasma pneumoniae | 1 | 2008 | 28 | 0.300 |
Why?
| | Apoptosis | 9 | 2015 | 2349 | 0.300 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2322 | 0.300 |
Why?
| | Lymphocyte Activation | 3 | 2009 | 1036 | 0.300 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 2 | 2005 | 10 | 0.300 |
Why?
| | Mice, Inbred CFTR | 4 | 2012 | 5 | 0.290 |
Why?
| | Chlorine | 3 | 2015 | 62 | 0.290 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2011 | 465 | 0.290 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2011 | 907 | 0.290 |
Why?
| | Mitochondria, Liver | 2 | 2004 | 67 | 0.280 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2011 | 637 | 0.280 |
Why?
| | Influenza, Human | 2 | 2023 | 543 | 0.270 |
Why?
| | Peroxidase | 3 | 2020 | 161 | 0.270 |
Why?
| | Carrier Proteins | 1 | 2010 | 694 | 0.260 |
Why?
| | Cisplatin | 1 | 2007 | 262 | 0.260 |
Why?
| | Neoplasms | 3 | 2014 | 2089 | 0.250 |
Why?
| | Mice, Knockout | 10 | 2015 | 2563 | 0.250 |
Why?
| | Administration, Oral | 5 | 2021 | 725 | 0.250 |
Why?
| | Disease Models, Animal | 11 | 2021 | 3499 | 0.250 |
Why?
| | Hydrogen Peroxide | 5 | 2012 | 288 | 0.240 |
Why?
| | Epilepsy, Temporal Lobe | 2 | 2015 | 20 | 0.240 |
Why?
| | Chronic Disease | 6 | 2017 | 1579 | 0.240 |
Why?
| | Hippocampus | 4 | 2017 | 690 | 0.240 |
Why?
| | Microsomes, Liver | 1 | 2005 | 54 | 0.240 |
Why?
| | Head and Neck Neoplasms | 1 | 2009 | 427 | 0.240 |
Why?
| | Monocytes | 2 | 2021 | 503 | 0.240 |
Why?
| | Pulmonary Fibrosis | 1 | 2008 | 321 | 0.240 |
Why?
| | Stavudine | 1 | 2004 | 8 | 0.240 |
Why?
| | Flavins | 1 | 2004 | 1 | 0.230 |
Why?
| | Nucleosides | 1 | 2004 | 25 | 0.220 |
Why?
| | Lipid Peroxidation | 7 | 2007 | 139 | 0.220 |
Why?
| | Pulmonary Edema | 1 | 2003 | 109 | 0.210 |
Why?
| | DNA Replication | 1 | 2004 | 202 | 0.210 |
Why?
| | Signal Transduction | 6 | 2020 | 4501 | 0.210 |
Why?
| | Bronchoalveolar Lavage | 2 | 2021 | 82 | 0.210 |
Why?
| | Anticonvulsants | 2 | 2017 | 178 | 0.210 |
Why?
| | Cells, Cultured | 8 | 2018 | 3862 | 0.200 |
Why?
| | Double-Blind Method | 2 | 2017 | 1656 | 0.200 |
Why?
| | Vaping | 1 | 2023 | 45 | 0.200 |
Why?
| | Lipopolysaccharides | 4 | 2016 | 813 | 0.200 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 73 | 0.190 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2008 | 960 | 0.190 |
Why?
| | Electrochemistry | 1 | 2002 | 79 | 0.190 |
Why?
| | Structure-Activity Relationship | 5 | 2012 | 499 | 0.190 |
Why?
| | Substrate Specificity | 3 | 2013 | 350 | 0.190 |
Why?
| | Pulmonary Alveoli | 2 | 2020 | 373 | 0.190 |
Why?
| | Aging | 2 | 2010 | 1612 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2016 | 1837 | 0.180 |
Why?
| | Oxygen | 4 | 2015 | 851 | 0.180 |
Why?
| | Administration, Inhalation | 3 | 2015 | 637 | 0.180 |
Why?
| | Adenocarcinoma | 1 | 2007 | 787 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1875 | 0.180 |
Why?
| | Brain | 3 | 2018 | 2355 | 0.180 |
Why?
| | Thiobarbituric Acid Reactive Substances | 4 | 2007 | 20 | 0.180 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 28 | 0.180 |
Why?
| | Burkholderia | 1 | 2020 | 13 | 0.170 |
Why?
| | Middle Aged | 9 | 2018 | 26621 | 0.170 |
Why?
| | Cyanates | 1 | 2019 | 4 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2017 | 159 | 0.170 |
Why?
| | Selenium Compounds | 1 | 2019 | 21 | 0.170 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 283 | 0.160 |
Why?
| | Glutamate-Cysteine Ligase | 2 | 2017 | 14 | 0.160 |
Why?
| | Particle Size | 1 | 2020 | 317 | 0.160 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 388 | 0.160 |
Why?
| | MPTP Poisoning | 2 | 2017 | 4 | 0.160 |
Why?
| | Morbidity | 1 | 2020 | 277 | 0.160 |
Why?
| | Mice, Hairless | 3 | 2014 | 74 | 0.160 |
Why?
| | Female | 18 | 2018 | 59349 | 0.160 |
Why?
| | Drug Synergism | 3 | 2012 | 315 | 0.150 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 298 | 0.150 |
Why?
| | Isoflurophate | 1 | 2018 | 5 | 0.150 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 14 | 0.150 |
Why?
| | Interleukin-13 | 1 | 2018 | 121 | 0.150 |
Why?
| | Neutrophils | 3 | 2020 | 1089 | 0.150 |
Why?
| | Kinetics | 2 | 2013 | 1547 | 0.140 |
Why?
| | Dimercaprol | 1 | 2017 | 6 | 0.140 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 26 | 0.140 |
Why?
| | Catalysis | 3 | 2008 | 289 | 0.130 |
Why?
| | Auranofin | 2 | 2013 | 9 | 0.130 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 845 | 0.130 |
Why?
| | Reactive Nitrogen Species | 2 | 2018 | 21 | 0.130 |
Why?
| | Cornea | 2 | 2007 | 102 | 0.130 |
Why?
| | Sulfhydryl Compounds | 2 | 2017 | 176 | 0.130 |
Why?
| | Aged | 5 | 2018 | 18973 | 0.130 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2007 | 102 | 0.130 |
Why?
| | Age Factors | 2 | 2015 | 2886 | 0.130 |
Why?
| | Neurons | 3 | 2018 | 1277 | 0.130 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 38 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 489 | 0.120 |
Why?
| | Intracellular Space | 2 | 2012 | 68 | 0.120 |
Why?
| | Thiourea | 2 | 2013 | 39 | 0.120 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 89 | 0.120 |
Why?
| | Mice, Inbred BALB C | 4 | 2013 | 1144 | 0.120 |
Why?
| | Comet Assay | 1 | 2014 | 18 | 0.120 |
Why?
| | Adult | 7 | 2016 | 30395 | 0.110 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 103 | 0.110 |
Why?
| | Drug Resistance, Multiple | 1 | 2014 | 19 | 0.110 |
Why?
| | Response Elements | 2 | 2012 | 82 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 2006 | 44 | 0.110 |
Why?
| | DNA Damage | 4 | 2009 | 351 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2011 | 81 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 97 | 0.110 |
Why?
| | Glycolysis | 1 | 2015 | 224 | 0.110 |
Why?
| | Biomarkers | 5 | 2018 | 3397 | 0.110 |
Why?
| | Hypochlorous Acid | 1 | 2013 | 4 | 0.110 |
Why?
| | Selenocysteine | 1 | 2013 | 3 | 0.110 |
Why?
| | Pollen | 1 | 2013 | 23 | 0.110 |
Why?
| | Cytoprotection | 2 | 2013 | 51 | 0.110 |
Why?
| | Bronchioles | 1 | 2013 | 22 | 0.110 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2013 | 44 | 0.110 |
Why?
| | Thioredoxin Reductase 2 | 1 | 2012 | 2 | 0.100 |
Why?
| | NADPH Oxidases | 1 | 2013 | 105 | 0.100 |
Why?
| | Bacteria | 1 | 2019 | 725 | 0.100 |
Why?
| | MAP Kinase Signaling System | 2 | 2017 | 271 | 0.100 |
Why?
| | Microbial Viability | 1 | 2013 | 79 | 0.100 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2010 | 107 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2005 | 1003 | 0.100 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1624 | 0.100 |
Why?
| | Antigens | 1 | 2014 | 317 | 0.100 |
Why?
| | Alveolar Epithelial Cells | 1 | 2013 | 93 | 0.100 |
Why?
| | Dopaminergic Neurons | 1 | 2012 | 43 | 0.100 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 261 | 0.100 |
Why?
| | Transcriptional Activation | 2 | 2011 | 337 | 0.100 |
Why?
| | Cysteine | 1 | 2013 | 171 | 0.100 |
Why?
| | Random Allocation | 4 | 2017 | 328 | 0.100 |
Why?
| | Extracellular Fluid | 1 | 2011 | 30 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 329 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 347 | 0.090 |
Why?
| | Antigen-Presenting Cells | 2 | 2009 | 150 | 0.090 |
Why?
| | Cognition Disorders | 1 | 2015 | 476 | 0.090 |
Why?
| | Blood-Brain Barrier | 3 | 2021 | 106 | 0.090 |
Why?
| | Phagocytosis | 2 | 2012 | 349 | 0.090 |
Why?
| | Copper | 2 | 2009 | 99 | 0.090 |
Why?
| | Fumarate Hydratase | 2 | 2011 | 2 | 0.090 |
Why?
| | Nasal Cavity | 1 | 2011 | 46 | 0.090 |
Why?
| | Aconitate Hydratase | 2 | 2011 | 16 | 0.090 |
Why?
| | Olfactory Mucosa | 1 | 2011 | 60 | 0.090 |
Why?
| | Asthma | 3 | 2013 | 2021 | 0.090 |
Why?
| | Myocardium | 3 | 2015 | 911 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 285 | 0.090 |
Why?
| | HIV Infections | 2 | 2004 | 2453 | 0.090 |
Why?
| | Dopamine | 2 | 2017 | 235 | 0.090 |
Why?
| | Bronchi | 1 | 2012 | 223 | 0.090 |
Why?
| | Irritants | 1 | 2010 | 41 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2014 | 665 | 0.090 |
Why?
| | Apoproteins | 1 | 2009 | 12 | 0.080 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 298 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 51 | 0.080 |
Why?
| | Dermatitis, Irritant | 1 | 2009 | 11 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 398 | 0.080 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 108 | 0.080 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2009 | 86 | 0.080 |
Why?
| | Fungal Proteins | 1 | 2010 | 119 | 0.080 |
Why?
| | Paraquat | 2 | 2012 | 14 | 0.080 |
Why?
| | Biological Transport | 1 | 2010 | 373 | 0.080 |
Why?
| | Demography | 1 | 2009 | 258 | 0.080 |
Why?
| | rho GTP-Binding Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | Amino Acids | 2 | 2010 | 445 | 0.080 |
Why?
| | Biocatalysis | 1 | 2008 | 58 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2003 | 1690 | 0.080 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2008 | 30 | 0.080 |
Why?
| | Body Fluids | 1 | 2008 | 58 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2009 | 719 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2009 | 137 | 0.080 |
Why?
| | Iron | 1 | 2009 | 232 | 0.070 |
Why?
| | Epilepsy | 1 | 2011 | 278 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2013 | 735 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 924 | 0.070 |
Why?
| | Time Factors | 2 | 2016 | 6077 | 0.070 |
Why?
| | Antiviral Agents | 2 | 2023 | 642 | 0.070 |
Why?
| | Electron Transport Complex I | 1 | 2007 | 33 | 0.070 |
Why?
| | Fibrosis | 1 | 2009 | 452 | 0.070 |
Why?
| | Neurofibromin 1 | 1 | 2007 | 22 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 742 | 0.070 |
Why?
| | Eye Proteins | 1 | 2007 | 70 | 0.070 |
Why?
| | Radiation-Protective Agents | 1 | 2007 | 26 | 0.070 |
Why?
| | Quality of Life | 1 | 2017 | 2346 | 0.070 |
Why?
| | Radiation Injuries, Experimental | 1 | 2007 | 24 | 0.070 |
Why?
| | Neurofibromatosis 1 | 1 | 2007 | 36 | 0.070 |
Why?
| | Intestinal Absorption | 1 | 2007 | 93 | 0.070 |
Why?
| | Dexamethasone | 2 | 2012 | 316 | 0.070 |
Why?
| | Pilocarpine | 2 | 2017 | 7 | 0.070 |
Why?
| | Cell Fractionation | 1 | 2006 | 51 | 0.070 |
Why?
| | HL-60 Cells | 1 | 2006 | 28 | 0.070 |
Why?
| | Saccharomyces cerevisiae | 1 | 2010 | 476 | 0.070 |
Why?
| | Mycoplasma Infections | 1 | 2006 | 13 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2009 | 1075 | 0.070 |
Why?
| | Stromal Cells | 1 | 2006 | 96 | 0.060 |
Why?
| | Leukemia, Myeloid | 1 | 2006 | 40 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 2007 | 90 | 0.060 |
Why?
| | Longevity | 1 | 2007 | 136 | 0.060 |
Why?
| | Corpus Striatum | 1 | 2007 | 126 | 0.060 |
Why?
| | Radiation Injuries | 1 | 2007 | 128 | 0.060 |
Why?
| | Models, Biological | 2 | 2010 | 1611 | 0.060 |
Why?
| | Drosophila melanogaster | 1 | 2007 | 188 | 0.060 |
Why?
| | Young Adult | 2 | 2023 | 10459 | 0.060 |
Why?
| | Cytochrome P-450 CYP2B1 | 1 | 2005 | 1 | 0.060 |
Why?
| | Caspase 8 | 1 | 2005 | 43 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2005 | 4 | 0.060 |
Why?
| | Xenobiotics | 1 | 2005 | 24 | 0.060 |
Why?
| | Cations | 1 | 2005 | 77 | 0.060 |
Why?
| | Aldehydes | 3 | 2012 | 138 | 0.060 |
Why?
| | Cataract | 1 | 2007 | 184 | 0.060 |
Why?
| | Nitric Oxide Synthase | 2 | 2003 | 209 | 0.060 |
Why?
| | Insulin | 1 | 2014 | 2080 | 0.060 |
Why?
| | Reperfusion Injury | 1 | 2007 | 252 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 108 | 0.060 |
Why?
| | Hypertension | 1 | 2012 | 1052 | 0.060 |
Why?
| | Oxidoreductases | 1 | 2005 | 89 | 0.060 |
Why?
| | Ferritins | 1 | 2004 | 52 | 0.060 |
Why?
| | Liver Diseases | 1 | 2007 | 254 | 0.060 |
Why?
| | Caspases | 1 | 2005 | 243 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1144 | 0.060 |
Why?
| | Cell Respiration | 2 | 2015 | 71 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2018 | 534 | 0.060 |
Why?
| | Ischemia | 1 | 2007 | 361 | 0.060 |
Why?
| | Glyoxylates | 1 | 2003 | 9 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2371 | 0.050 |
Why?
| | Sulfonylurea Compounds | 1 | 2003 | 44 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 90 | 0.050 |
Why?
| | Half-Life | 2 | 2017 | 141 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2003 | 302 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 210 | 0.050 |
Why?
| | Parkinson Disease | 1 | 2007 | 346 | 0.050 |
Why?
| | Probability | 1 | 2003 | 286 | 0.050 |
Why?
| | Cardiomyopathies | 1 | 2006 | 298 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 384 | 0.050 |
Why?
| | Cell Death | 2 | 2015 | 322 | 0.050 |
Why?
| | Adolescent | 2 | 2023 | 17811 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 140 | 0.050 |
Why?
| | Nitric Acid | 1 | 2002 | 5 | 0.050 |
Why?
| | Endotoxemia | 1 | 2003 | 86 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 434 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 739 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 256 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1228 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 990 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 206 | 0.050 |
Why?
| | Iraq | 1 | 2021 | 81 | 0.050 |
Why?
| | Injury Severity Score | 1 | 2003 | 472 | 0.050 |
Why?
| | Epithelium | 1 | 2022 | 295 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 222 | 0.050 |
Why?
| | Mitochondria, Heart | 2 | 2015 | 72 | 0.050 |
Why?
| | Eosinophils | 1 | 2003 | 276 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2021 | 285 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 2505 | 0.040 |
Why?
| | Glutathione Disulfide | 2 | 2011 | 26 | 0.040 |
Why?
| | Blood Pressure | 2 | 2003 | 1531 | 0.040 |
Why?
| | Estrogens | 1 | 2002 | 312 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2017 | 771 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 926 | 0.040 |
Why?
| | Cohort Studies | 2 | 2012 | 4885 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2003 | 614 | 0.040 |
Why?
| | Liver | 1 | 2007 | 1633 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 561 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 913 | 0.040 |
Why?
| | Soman | 1 | 2018 | 1 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 20 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 35 | 0.040 |
Why?
| | Tyrosine | 2 | 2011 | 210 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1356 | 0.040 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 333 | 0.040 |
Why?
| | Toll-Like Receptor 2 | 1 | 2018 | 110 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1735 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2018 | 191 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2003 | 817 | 0.040 |
Why?
| | Gene Expression | 2 | 2013 | 1417 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2018 | 229 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 1143 | 0.040 |
Why?
| | Mice, Inbred NOD | 2 | 2014 | 552 | 0.040 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2017 | 2 | 0.040 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.040 |
Why?
| | RNA | 1 | 2023 | 806 | 0.040 |
Why?
| | Transfection | 2 | 2012 | 863 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2011 | 157 | 0.040 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 99 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 119 | 0.030 |
Why?
| | Proteins | 1 | 2003 | 906 | 0.030 |
Why?
| | Microglia | 1 | 2018 | 198 | 0.030 |
Why?
| | Nervous System | 1 | 2017 | 63 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2017 | 137 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2003 | 637 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3007 | 0.030 |
Why?
| | Drug Design | 1 | 2017 | 147 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 3315 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 830 | 0.030 |
Why?
| | Nootropic Agents | 1 | 2015 | 27 | 0.030 |
Why?
| | Etiocholanolone | 1 | 2015 | 7 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 743 | 0.030 |
Why?
| | Ranolazine | 1 | 2015 | 22 | 0.030 |
Why?
| | Kainic Acid | 1 | 2015 | 31 | 0.030 |
Why?
| | DNA Polymerase gamma | 2 | 2006 | 7 | 0.030 |
Why?
| | Military Personnel | 1 | 2021 | 522 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 121 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2008 | 9051 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2017 | 459 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 176 | 0.030 |
Why?
| | Betula | 1 | 2013 | 3 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2015 | 213 | 0.030 |
Why?
| | Oxidopamine | 1 | 2012 | 12 | 0.030 |
Why?
| | PPAR delta | 1 | 2012 | 6 | 0.030 |
Why?
| | Interferon-beta | 1 | 2013 | 79 | 0.030 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 28 | 0.030 |
Why?
| | Peroxiredoxins | 1 | 2012 | 23 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2012 | 44 | 0.030 |
Why?
| | Lentivirus | 1 | 2012 | 45 | 0.030 |
Why?
| | Mesencephalon | 1 | 2012 | 57 | 0.030 |
Why?
| | Papio | 2 | 2003 | 96 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2014 | 3254 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 1726 | 0.030 |
Why?
| | Motor Activity | 1 | 2017 | 635 | 0.030 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2012 | 13 | 0.020 |
Why?
| | Prospective Studies | 1 | 2003 | 6198 | 0.020 |
Why?
| | Th2 Cells | 1 | 2013 | 154 | 0.020 |
Why?
| | NF-E2 Transcription Factor, p45 Subunit | 1 | 2012 | 3 | 0.020 |
Why?
| | Emphysema | 1 | 2013 | 106 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 909 | 0.020 |
Why?
| | Coenzyme A | 1 | 2011 | 6 | 0.020 |
Why?
| | Holoenzymes | 1 | 2012 | 21 | 0.020 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 18 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 300 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 142 | 0.020 |
Why?
| | NAD | 1 | 2011 | 63 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2012 | 130 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2012 | 2550 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 754 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2012 | 256 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2015 | 449 | 0.020 |
Why?
| | Buthionine Sulfoximine | 1 | 2010 | 7 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 192 | 0.020 |
Why?
| | Dermatitis | 1 | 2010 | 17 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 286 | 0.020 |
Why?
| | Skinfold Thickness | 1 | 2010 | 49 | 0.020 |
Why?
| | Fibroblasts | 2 | 2006 | 836 | 0.020 |
Why?
| | Deoxyadenosines | 1 | 2009 | 7 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 589 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 300 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 359 | 0.020 |
Why?
| | Oncogene Protein v-akt | 1 | 2009 | 26 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2009 | 30 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 777 | 0.020 |
Why?
| | Phenotype | 2 | 2007 | 2784 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 102 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2009 | 108 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 522 | 0.020 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2009 | 72 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1218 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2009 | 154 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2011 | 380 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2009 | 80 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2012 | 526 | 0.020 |
Why?
| | Cell Cycle | 1 | 2010 | 541 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2012 | 727 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2007 | 33 | 0.020 |
Why?
| | Nitrosation | 1 | 2007 | 8 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1368 | 0.020 |
Why?
| | Membrane Lipids | 1 | 2007 | 87 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2007 | 134 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 133 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 1888 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2007 | 85 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 569 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 27 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2007 | 241 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2007 | 225 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2007 | 215 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 141 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 303 | 0.020 |
Why?
| | Etoposide | 1 | 2006 | 149 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 42 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1310 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 636 | 0.020 |
Why?
| | Heart | 1 | 2009 | 613 | 0.020 |
Why?
| | Rabbits | 1 | 2006 | 733 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 714 | 0.020 |
Why?
| | Radioisotopes | 1 | 2004 | 28 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 363 | 0.010 |
Why?
| | fas Receptor | 1 | 2004 | 91 | 0.010 |
Why?
| | Phagocytes | 1 | 2004 | 90 | 0.010 |
Why?
| | Renal Blood Flow, Effective | 1 | 2003 | 2 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2004 | 188 | 0.010 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 12 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 74 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 353 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 73 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2002 | 136 | 0.010 |
Why?
| | DNA Polymerase beta | 1 | 2002 | 5 | 0.010 |
Why?
| | Permeability | 1 | 2003 | 149 | 0.010 |
Why?
| | Estrone | 1 | 2002 | 35 | 0.010 |
Why?
| | DNA Polymerase I | 1 | 2002 | 26 | 0.010 |
Why?
| | Linoleic Acid | 1 | 2002 | 37 | 0.010 |
Why?
| | Ions | 1 | 2002 | 59 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2003 | 247 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2002 | 16 | 0.010 |
Why?
| | S-Nitrosoglutathione | 1 | 2002 | 6 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2002 | 133 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2002 | 33 | 0.010 |
Why?
| | PC12 Cells | 1 | 2002 | 37 | 0.010 |
Why?
| | Free Radicals | 1 | 2002 | 99 | 0.010 |
Why?
| | Insulinoma | 1 | 2002 | 29 | 0.010 |
Why?
| | Electrons | 1 | 2002 | 71 | 0.010 |
Why?
| | Dogs | 1 | 2002 | 331 | 0.010 |
Why?
| | Hyperoxia | 1 | 2003 | 99 | 0.010 |
Why?
| | Hormone Replacement Therapy | 1 | 2002 | 76 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 188 | 0.010 |
Why?
| | Clone Cells | 1 | 2002 | 247 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 269 | 0.010 |
Why?
| | Occupational Exposure | 1 | 2004 | 256 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 137 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 135 | 0.010 |
Why?
| | Mice, SCID | 1 | 2002 | 312 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2006 | 723 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2006 | 1947 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 386 | 0.010 |
Why?
| | Models, Chemical | 1 | 2002 | 248 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 160 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2003 | 605 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 787 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 1981 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2002 | 587 | 0.010 |
Why?
| | Swine | 1 | 2002 | 687 | 0.010 |
Why?
| | Estradiol | 1 | 2002 | 450 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 918 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 388 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2002 | 622 | 0.010 |
Why?
| | Fatty Acids | 1 | 2002 | 380 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 1638 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2783 | 0.010 |
Why?
| | Fetus | 1 | 2003 | 698 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 615 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1181 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1089 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 3338 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3039 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 5039 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 1846 | 0.010 |
Why?
|
|
Day's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|